Tech Company Financing Transactions
Dewpoint Therapeutics Funding Round
Arch Venture Partners, Bellco Capital and EcoR1 Capital Management invested in a $77 million Series B funding round for Dewpoint Therapeutics. The financing was announced by the company on 9/30/2020.
Transaction Overview
Company Name
Announced On
9/30/2020
Transaction Type
Venture Equity
Amount
$77,000,000
Round
Series B
Investors
Proceeds Purpose
This series B round will help Dewpoint ramp up the work on the aforementioned diseases and others, including neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and certain cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6 Tide St. 300
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Dewpoint is translating new insights into biomolecular condensates and cellular function to uncover treatments for the toughest diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amir Nashat
Chief Operating Officer
Bruce Beutel
Chief Scientific Officer
Mark Murcko
Founder
Anthony Hyman
Founder
Richard Young
Vice President
William Chen
Vice President
Peter Dandliker
Vice President
Stephen Hale
Vice President
Alexander Szewczak
Vice President
Rebecca Zacks
VP - Bus. Development
Scott Peterson
VP - Human Resources
Holly Abernethy
VP - R & D
Ann Kwong
Browse more venture capital transactions:
Prev: 9/30/2020: Elevate Security venture capital transaction
Next: 10/1/2020: Talos venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs